AAAAAA

   
Results: 1-17 |
Results: 17
IODINE-131-LABELED ANTITENASCIN MONOCLONAL-ANTIBODY 81C6 TREATMENT OFPATIENTS WITH RECURRENT MALIGNANT GLIOMAS - PHASE-I TRIAL RESULTS
Authors: BIGNER DD BROWN MT FRIEDMAN AH COLEMAN RE AKABANI G FRIEDMAN HS THORSTAD WL MCLENDON RE BIGNER SH ZHAO XG PEGRAM CN WIKSTRAND CJ HERNDON JE VICK NA PALEOLOGOS N COKGOR I PROVENZALE JM ZALUTSKY MR
Citation: Dd. Bigner et al., IODINE-131-LABELED ANTITENASCIN MONOCLONAL-ANTIBODY 81C6 TREATMENT OFPATIENTS WITH RECURRENT MALIGNANT GLIOMAS - PHASE-I TRIAL RESULTS, Journal of clinical oncology, 16(6), 1998, pp. 2202-2212
LOCALLY INCREASED UPTAKE OF FLUORINE-19-FLUORODEOXYGLUCOSE AFTER INTRACAVITARY ADMINISTRATION OF IODINE-131-LABELED ANTIBODY FOR PRIMARY BRAIN-TUMORS
Authors: MARRIOTT CJC THORSTAD W AKABANI G BROWN MT MCLENDON RE HANSON MW COLEMAN RE
Citation: Cjc. Marriott et al., LOCALLY INCREASED UPTAKE OF FLUORINE-19-FLUORODEOXYGLUCOSE AFTER INTRACAVITARY ADMINISTRATION OF IODINE-131-LABELED ANTIBODY FOR PRIMARY BRAIN-TUMORS, The Journal of nuclear medicine, 39(8), 1998, pp. 1376-1380
WORSENING MR AND PET FINDINGS DO NOT NECESSARILY INDICATE TUMOR PROGRESSION IN PATIENTS WITH RESECTED PRIMARY BRAIN-TUMORS UNDERGOING TREATMENT WITH INTRACAVITARY IODINE-131-LABELED ANTI-TENASCIN MONOCLONAL-ANTIBODY
Authors: PROVENZALE JM RODRIGUEZ D COLEMAN RE FRIEDMAN HS AKABANI G COKGOR I
Citation: Jm. Provenzale et al., WORSENING MR AND PET FINDINGS DO NOT NECESSARILY INDICATE TUMOR PROGRESSION IN PATIENTS WITH RESECTED PRIMARY BRAIN-TUMORS UNDERGOING TREATMENT WITH INTRACAVITARY IODINE-131-LABELED ANTI-TENASCIN MONOCLONAL-ANTIBODY, Radiology, 209P, 1998, pp. 256-256
THE CYTOTOXICITY AND MICRODOSIMETRY OF ASTATINE-211-LABELED CHIMERIC MONOCLONAL-ANTIBODIES IN HUMAN GLIOMA AND MELANOMA-CELLS IN-VITRO
Authors: LARSEN RH AKABANI G WELSH P ZALUTSKY MR
Citation: Rh. Larsen et al., THE CYTOTOXICITY AND MICRODOSIMETRY OF ASTATINE-211-LABELED CHIMERIC MONOCLONAL-ANTIBODIES IN HUMAN GLIOMA AND MELANOMA-CELLS IN-VITRO, Radiation research, 149(2), 1998, pp. 155-162
RESULTS OF A PHASE-I TRIAL OF PATIENTS WITH RECURRENT BRAIN-TUMORS AND PRIOR RADIATION-THERAPY TREATED WITH I-131-LABELED ANTITENASCIN MONOCLONAL-ANTIBODY 81C6 VIA SURGICALLY CREATED RESECTION CAVITIES
Authors: COKGOR I AKABANI G BROWN MT FRIEDMAN AH COLEMAN RE FRIEDMAN HS THORSTAD WL MCLENDON RE BIGNER SH ZHAO XG PEGRAM CN WIKSTRAND CJ HERNDON JE VICK NA PALEOLOGOS N ZALUTSKY MR BIGNER DD
Citation: I. Cokgor et al., RESULTS OF A PHASE-I TRIAL OF PATIENTS WITH RECURRENT BRAIN-TUMORS AND PRIOR RADIATION-THERAPY TREATED WITH I-131-LABELED ANTITENASCIN MONOCLONAL-ANTIBODY 81C6 VIA SURGICALLY CREATED RESECTION CAVITIES, Neurology, 50(4), 1998, pp. 52005-52005
I-131 LL2 (ANTI-CD22) RADIOIMMUNOTHERAPY (RIT) OF REFRACTORY NON-HODGKINS-LYMPHOMA (NHL) - RESULTS OF A REPETITIVE DOSING TRIAL
Authors: VOSE J COLCHER D BIERMAN P LEICHNER P AKABANI G HARRISON K HOHENSTEIN M LESSER S HAMMERSHAIMB L GOLDENBERG DM TEMPERO M ARMITAGE J
Citation: J. Vose et al., I-131 LL2 (ANTI-CD22) RADIOIMMUNOTHERAPY (RIT) OF REFRACTORY NON-HODGKINS-LYMPHOMA (NHL) - RESULTS OF A REPETITIVE DOSING TRIAL, The Journal of nuclear medicine, 38(5), 1997, pp. 211-211
DOSIMETRY METHODS FOR PATIENTS WITH MALIGNANT CNS TUMORS TREATED WITHI-131 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY
Authors: AKABANI G THORSTAD WL BROWN MT COLEMAN RE ZALUTSKY MR BIGNER DD
Citation: G. Akabani et al., DOSIMETRY METHODS FOR PATIENTS WITH MALIGNANT CNS TUMORS TREATED WITHI-131 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY, The Journal of nuclear medicine, 38(5), 1997, pp. 395-395
MICRODOSIMETRY AND SMALL-SCALE DOSIMETRY OF AT-211 IN BONE-MARROW - AN ANALYSIS BASED ON HISTOLOGICAL IMAGING
Authors: AKABANI G ZALUTSKY MR
Citation: G. Akabani et Mr. Zalutsky, MICRODOSIMETRY AND SMALL-SCALE DOSIMETRY OF AT-211 IN BONE-MARROW - AN ANALYSIS BASED ON HISTOLOGICAL IMAGING, The Journal of nuclear medicine, 38(5), 1997, pp. 963-963
PATIENT-SPECIFIC DOSIMETRY OF INDIUM-111-LABELED AND YTTRIUM-90-LABELED MONOCLONAL-ANTIBODY CC49
Authors: LEICHNER PK AKABANI G COLCHER D HARRISON KA HAWKINS WG ECKBLADE M BARANOWSKAKORTYLEWICZ J AUGUSTINE SC WISECARVER J TEMPERO MA
Citation: Pk. Leichner et al., PATIENT-SPECIFIC DOSIMETRY OF INDIUM-111-LABELED AND YTTRIUM-90-LABELED MONOCLONAL-ANTIBODY CC49, The Journal of nuclear medicine, 38(4), 1997, pp. 512-516
PATIENT-SPECIFIC DOSIMETRY USING QUANTITATIVE SPECT IMAGING AND 3-DIMENSIONAL DISCRETE FOURIER-TRANSFORM CONVOLUTION
Authors: AKABANI G HAWKINS WG ECKBLADE MB LEICHNER PK
Citation: G. Akabani et al., PATIENT-SPECIFIC DOSIMETRY USING QUANTITATIVE SPECT IMAGING AND 3-DIMENSIONAL DISCRETE FOURIER-TRANSFORM CONVOLUTION, The Journal of nuclear medicine, 38(2), 1997, pp. 308-314
MICRODOSIMETRY OF ASTATINE-211 USING HISTOLOGICAL IMAGES - APPLICATION TO BONE-MARROW
Authors: AKABANI G ZALUTSKY MR
Citation: G. Akabani et Mr. Zalutsky, MICRODOSIMETRY OF ASTATINE-211 USING HISTOLOGICAL IMAGES - APPLICATION TO BONE-MARROW, Radiation research, 148(6), 1997, pp. 599-607
PATIENT-SPECIFIC DOSIMETRY BASED ON QUANTITATIVE SPECT IMAGING AND 3D-DFT CONVOLUTION - A COMPARISON WITH MONTE-CARLO TRANSPORT CALCULATIONS
Authors: AKABANI G HAWKINS WG ECKBLADE MB LEICHNER PK
Citation: G. Akabani et al., PATIENT-SPECIFIC DOSIMETRY BASED ON QUANTITATIVE SPECT IMAGING AND 3D-DFT CONVOLUTION - A COMPARISON WITH MONTE-CARLO TRANSPORT CALCULATIONS, The Journal of nuclear medicine, 37(5), 1996, pp. 347-347
PATIENT-SPECIFIC DOSIMETRY OF IN-111- Y-90-LABELED MONOCLONAL-ANTIBODY CC49/
Authors: LEICHNER PK AKABANI G COLCHER DM HARRISON KA HAWKINS WG BARANOWSKAKORTELYWICZ J ECKBLADE M AUGUSTINE SC TEMPERO MA
Citation: Pk. Leichner et al., PATIENT-SPECIFIC DOSIMETRY OF IN-111- Y-90-LABELED MONOCLONAL-ANTIBODY CC49/, The Journal of nuclear medicine, 37(5), 1996, pp. 350-350
SMALL-SCALE ALPHA-DOSIMETRY OF RED BONE-MARROW USING HISTOLOGICAL IMAGES
Authors: AKABANI G HAWKINS WG LEICHNER PK
Citation: G. Akabani et al., SMALL-SCALE ALPHA-DOSIMETRY OF RED BONE-MARROW USING HISTOLOGICAL IMAGES, The Journal of nuclear medicine, 37(5), 1996, pp. 1042-1042
THERAPY OF REFRACTORY NON-HODGKINS-LYMPHOMA (NHL) WITH I-131 LL2 (ANTI-CD22) RADIOIMMUNOTHERAPY (RIT) - RESULTS OF A REPETITIVE DOSING TRIAL
Authors: VOSE J COLCHER D BIERMAN P LEICHNER P AKABANI G HARRISON K HOHENSTEIN M LESSER S HAMMERSHAIMB L GOLDENBERG DM TEMPERO M ARMITAGE J
Citation: J. Vose et al., THERAPY OF REFRACTORY NON-HODGKINS-LYMPHOMA (NHL) WITH I-131 LL2 (ANTI-CD22) RADIOIMMUNOTHERAPY (RIT) - RESULTS OF A REPETITIVE DOSING TRIAL, Blood, 88(10), 1996, pp. 2258-2258
ABSORBED DOSE CALCULATIONS IN HAVERSIAN CANALS FOR SEVERAL BETA-EMITTING RADIONUCLIDES
Authors: AKABANI G
Citation: G. Akabani, ABSORBED DOSE CALCULATIONS IN HAVERSIAN CANALS FOR SEVERAL BETA-EMITTING RADIONUCLIDES, The Journal of nuclear medicine, 34(8), 1993, pp. 1361-1366
MIRD DOSE ESTIMATE REPORT NO-17 - RADIATION ABSORBED DOSE ESTIMATES FROM INHALED KRYPTON-81M GAS IN LUNG IMAGING
Authors: ATKINS HL ROBERTSON JS AKABANI G
Citation: Hl. Atkins et al., MIRD DOSE ESTIMATE REPORT NO-17 - RADIATION ABSORBED DOSE ESTIMATES FROM INHALED KRYPTON-81M GAS IN LUNG IMAGING, The Journal of nuclear medicine, 34(8), 1993, pp. 1382-1384
Risultati: 1-17 |